Article
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Cancer immunology, immunotherapy : CII - 1 Jan 1993
Weiner L M, Hudes G R, Kitson J, Walczak J, Watts P, Litwin S, O'Dwyer P J
Abstract excerpt
In a phase II clinical trial of 5-fluorouracil (5FU) plus N-(phosphonacetyl)-L-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
